Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
Quantum BioPharma reached the halfway enrollment milestone in its collaborative imaging study with Massachusetts General Hospital, reporting encouraging preliminary results. The study validates a novel PET tracer, [¹⁸F]3F4AP, which can directly assess demyelinated neurons with intact axons in multiple sclerosis patients, offering a potential biomarker for tracking disease progression and treatment response.
Key figures
- Drug Name
- Lucid-MS (Lucid-21-302)
- Phase Of Trial
- Phase 2
- Royalty cap
- $250 million
- Imaging tracer
- [¹⁸F]3F4AP
- Royalty rate initial
- 7%
- Royalty rate post cap
- 3%
- Unbuzzd ownership pct
- 19.84
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.